173 filings
Page 5 of 9
8-K
uhbdx 0om
19 Aug 20
Timber Pharmaceuticals Announces Appointment of Dr. David Cohen and Dr. Lubor Gaal to Board of Directors
4:27pm
8-K
glcvlo9h 8n4s784bc
18 Aug 20
Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2020 Financial Results
4:54pm
8-K/A
efnvjy9g3
2 Jul 20
Changes in Registrant's Certifying Accountant
5:15pm
8-K
gcdnb4x8 y5s
3 Jun 20
Entry into a Material Definitive Agreement
4:06pm
8-K
b5wy6r3
22 May 20
Timber Pharmaceuticals Announces Merger Closing
5:16pm
8-K
iihe vqx41t4
15 May 20
BioPharmX Announces 1-for-12 Reverse Stock Split
4:30pm
8-K
fjlkcs
13 May 20
BioPharmX Corporation Announces Approval of Merger by Stockholders at Special Meeting
4:33pm
8-K
qetdk64f0
11 May 20
Other Events
4:08pm
8-K
df40m4
27 Apr 20
BioPharmX Corporation Announces that its Special Stockholders’ Meeting
4:12pm
8-K
stt4w8vn3r5t flo5zp
6 Apr 20
Timber Pharmaceuticals Announces Award of Second Tranche of FDA Orphan Products Clinical Trials Grant
4:54pm
8-K
syr 9j5p990
30 Mar 20
BioPharmX Receives Notice of Delisting from NYSE American But Stock will Remain Trading
4:03pm
8-K
zwnib19
18 Feb 20
Entry into a Material Definitive Agreement
4:04pm
8-K
iegi4t22ed
3 Feb 20
Departure of Directors or Certain Officers
9:00am
8-K
2hmjvvcg1p
29 Jan 20
BioPharmX and Timber Pharmaceuticals Announce Entry into Merger Agreement
4:33pm
8-K
58ikord0p22u75kdxno
10 Dec 19
BioPharmX Reports Fiscal Third Quarter 2020 Financial Results and Provides Corporate Update
4:06pm
8-K
y6b5h5idah8p3h2qih
20 Sep 19
BioPharmX Receives Notice of Compliance Deadline Extension from NYSE American
4:08pm
8-K
h15rwyo3obf6a1u1901i
9 Sep 19
BioPharmX Reports Fiscal Second Quarter 2020 Financial Results and Provides Corporate Update
8:16am
8-K
ha3gydtt 37
17 Jul 19
BioPharmX Announces Steven M. Bosacki Joins the Company as Chief Operating Officer
4:12pm
8-K
4myevidlw69b 6dn8
11 Jul 19
Submission of Matters to a Vote of Security Holders
4:25pm
8-K
cpf4x2nwp ga
25 Jun 19
BioPharmX Announces Positive Topline Results from Phase 2b Trial of BPX-04 for Papulopustular Rosacea
8:00am